|

SHR-A1921 Clinical Trials

4 actively recruiting trials

Pipeline

Phase 2: 3Phase 3: 1

Top Sponsors

  • Fudan University3
  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1

Indications

  • Cancer4
  • HER2-negative Breast Cancer3
  • Breast Cancer3
  • Hormone Receptor Positive Tumor2
  • Triple Negative Breast Cancer (TNBC)2

Other4 trials

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Phase 3
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.